Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 2/3 1Phase 1 1

Status

Withdrawn 1Unknown 1Terminated 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 2CNS 1

Conditions

Breast Neoplasms 2Neoplasm Metastasis 1Brain Neoplasms 1

Interventions

Cyclophosphamide 3155Cisplatin 3151Carboplatin 2929Paclitaxel 2671Radiotherapy 2643Gemcitabine 2544pembrolizumab 2324Docetaxel 2154Bevacizumab 2126Fluorouracil 1819Capecitabine 1780Oxaliplatin 1709Dexamethasone 1589Nivolumab 1516Doxorubicin 1477Rituximab 1453Etoposide 1341Magnetic Resonance Spectroscopy 1261Irinotecan 1232Leucovorin 1212Cytarabine 1123Pemetrexed 1060Drug Therapy 1060fludarabine 1044Vincristine 956Specimen Handling 928Prednisone 924Cetuximab 919Lenalidomide 916Trastuzumab 897

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × gancotamab × Clear all
NCT02735798 2017-05-04

64-Cu Labeled Brain PET/MRI for MM-302 in Advanced HER2+ Cancers With Brain Mets

University of California, San Francisco

Phase EARLY_PHASE1 Withdrawn
CNS

Brain Neoplasms

NCT01304797 2017-01-06

Safety and Pharmacokinetic Study of MM-302 in Patients With Advanced Breast Cancer

Merrimack Pharmaceuticals

Phase 1 Unknown
75 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis

NCT02213744 2017-01-06

HERMIONE

Merrimack Pharmaceuticals

Phase 2/3 Terminated
113 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡